Skip to main
HIMS
HIMS logo

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 27%
Buy 0%
Hold 55%
Sell 9%
Strong Sell 9%

Bulls say

Hims & Hers Health is projected to experience significant revenue growth, with an estimated increase in international revenue from approximately $50 million in FY25 to nearly $1 billion by FY30, reflecting a tenfold enhancement driven by the expansion of treatment options and international market entry. Additionally, core U.S. revenue is forecasted to grow at an annual rate of about 21%, primarily fueled by a rise in subscriber numbers and enhancements to revenue per subscriber through personalization and new treatment offerings. The growing trend towards private healthcare, particularly in markets such as the UK, further supports the positive outlook, as evidenced by a notable increase in private insurance adoption in recent years.

Bears say

Hims & Hers Health has experienced a significant decline in stock value, dropping over 20% since late July despite an initial doubling of shares year-to-date, indicating growing concerns regarding slowing core growth. Key risks include the potential for slower adoption of personalized treatments, regulatory challenges that could affect the business model, difficulties in maintaining revenue growth while achieving operating leverage, and increasing competition in the digital health sector. These factors contribute to a negative outlook for the company's financial performance moving forward.

HIMS has been analyzed by 11 analysts, with a consensus rating of Hold. 27% of analysts recommend a Strong Buy, 0% recommend Buy, 55% suggest Holding, 9% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 11 analysts, HIMS has a Hold consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.